EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies

Saskia E Mudde iD, Henriëtte M Meliefste, Corné H W Klaassen iD, Nicole C Ammerman, Jessica V Pierce, Alisa W Serio iD, Jurriaan E M De Steenwinkel, Hannelore I Bax

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Saskia E Mudde und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Tetracyclines, Mycobacterium avium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Paratek Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The current antibiotic arsenal for the treatment of Mycobacterium avium infections is limited and new treatment options are needed. This exploratory study assessed the in vitro activity of omadacycline against M. avium alone and combined with current guideline-recommended antibiotics and the ability of omadacycline to prevent the emergence of antibiotic resistance.

Methods

The activity of omadacycline and comparator antibiotics against M. avium was studied by minimum inhibitory concentration (MIC) assays and time-kill kinetics assays to investigate time- and concentration-dependent activity patterns. Omadacycline’s ability to prevent clarithromycin and amikacin resistance was investigated by phenotypic and molecular assays.

Results

The MIC of omadacycline was impacted by medium composition: a higher MIC was found in CAMHB (128 mg/L) versus Middlebrook broth (8 mg/L). MIC values were also impacted by omadacycline instability in solution over time and daily drug supplementation reduced the MIC to 1 mg/L. In time-kill assays, omadacycline demonstrated time- and concentration-dependent activity. Omadacycline-containing drug combinations resulted in varying degrees of enhanced activity, which was most apparent for omadacycline plus amikacin. Omadacycline prevented amikacin MICs from increasing and impeded the emergence of rrs mutations observed with amikacin alone. While enhanced activity of omadacycline plus clarithromycin was less pronounced, rrl mutations were not detected in the presence of omadacycline.

Conclusions

Omadacycline demonstrated in vitro activity against M. avium, particularly in combination with amikacin. Emergence of clarithromycin and amikacin resistance seemed to be prevented by co-exposure to omadacycline. Further research is warranted to assess omadacycline’s role in treating M. avium disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsTetracyclinesMycobacterium aviumMicrobial Sensitivity TestsHumansClarithromycinAmikacinDrug Resistance, BacterialMicrobial ViabilityMycobacterium avium-intracellulare InfectionDrug Therapy, CombinationCulture MediaTime Factors

Substanzen

Anti-Bacterial AgentsomadacyclineTetracyclinesClarithromycinAmikacinCulture Media

Autor:innen und Institutionen

  • Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA.
  • Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands.

ORCID-Profile: Saskia E Mudde, Corné H W Klaassen, Alisa W Serio

Förderung

  • Paratek Pharmaceuticals

Zitieren

APA

Mudde, S. E., Meliefste, H. M., Klaassen, C. H. W., Ammerman, N. C., Pierce, J. V., Serio, A. W., De Steenwinkel, J. E. M., & Bax, H. I. (2026). Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf413

Vancouver

Mudde SE, Meliefste HM, Klaassen CHW, Ammerman NC, Pierce JV, Serio AW, et al. Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf413

BibTeX
@article{Mudde2026,
  author = {Mudde, Saskia E and Meliefste, Henriëtte M and Klaassen, Corné H W and Ammerman, Nicole C and Pierce, Jessica V and Serio, Alisa W and De Steenwinkel, Jurriaan E M and Bax, Hannelore I},
  title = {Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf413}
}
Kostenlos starten →